CA2981303C - Assay for detecting closely-related serotypes of human papillomavirus (hpv) - Google Patents
Assay for detecting closely-related serotypes of human papillomavirus (hpv) Download PDFInfo
- Publication number
- CA2981303C CA2981303C CA2981303A CA2981303A CA2981303C CA 2981303 C CA2981303 C CA 2981303C CA 2981303 A CA2981303 A CA 2981303A CA 2981303 A CA2981303 A CA 2981303A CA 2981303 C CA2981303 C CA 2981303C
- Authority
- CA
- Canada
- Prior art keywords
- primer
- probe set
- seq
- sequences
- nos
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241000701806 Human papillomavirus Species 0.000 title claims abstract description 337
- 238000003556 assay Methods 0.000 title claims description 63
- 239000000523 sample Substances 0.000 claims abstract description 501
- 108091034117 Oligonucleotide Proteins 0.000 claims abstract description 152
- 238000001514 detection method Methods 0.000 claims abstract description 38
- 239000012472 biological sample Substances 0.000 claims abstract 7
- 239000013615 primer Substances 0.000 claims description 503
- 230000000295 complement effect Effects 0.000 claims description 128
- 239000002773 nucleotide Substances 0.000 claims description 41
- 125000003729 nucleotide group Chemical group 0.000 claims description 40
- 239000002987 primer (paints) Substances 0.000 claims description 17
- 238000009396 hybridization Methods 0.000 claims description 15
- 239000002751 oligonucleotide probe Substances 0.000 claims description 14
- 108020005187 Oligonucleotide Probes Proteins 0.000 claims description 12
- 239000003155 DNA primer Substances 0.000 claims description 10
- 238000007837 multiplex assay Methods 0.000 claims description 10
- 238000012544 monitoring process Methods 0.000 claims 2
- 238000002944 PCR assay Methods 0.000 abstract description 3
- 230000003321 amplification Effects 0.000 description 28
- 238000003199 nucleic acid amplification method Methods 0.000 description 28
- 238000003752 polymerase chain reaction Methods 0.000 description 24
- 150000007523 nucleic acids Chemical class 0.000 description 23
- 108090000623 proteins and genes Proteins 0.000 description 23
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 17
- 102000054765 polymorphisms of proteins Human genes 0.000 description 17
- 101150071673 E6 gene Proteins 0.000 description 15
- 238000006243 chemical reaction Methods 0.000 description 15
- 238000000034 method Methods 0.000 description 15
- 108020004707 nucleic acids Proteins 0.000 description 14
- 102000039446 nucleic acids Human genes 0.000 description 14
- 230000000875 corresponding effect Effects 0.000 description 12
- 108091093088 Amplicon Proteins 0.000 description 10
- 239000000975 dye Substances 0.000 description 9
- 108020004414 DNA Proteins 0.000 description 8
- 230000011664 signaling Effects 0.000 description 8
- 108091028043 Nucleic acid sequence Proteins 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 239000007850 fluorescent dye Substances 0.000 description 6
- 230000035772 mutation Effects 0.000 description 6
- 238000003753 real-time PCR Methods 0.000 description 6
- 238000012408 PCR amplification Methods 0.000 description 5
- 238000000137 annealing Methods 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 101150013359 E7 gene Proteins 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 239000007790 solid phase Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- 102100031780 Endonuclease Human genes 0.000 description 2
- 108060002716 Exonuclease Proteins 0.000 description 2
- 238000009015 Human TaqMan MicroRNA Assay kit Methods 0.000 description 2
- 241000341655 Human papillomavirus type 16 Species 0.000 description 2
- 108091092195 Intron Proteins 0.000 description 2
- 108010006785 Taq Polymerase Proteins 0.000 description 2
- 102000006943 Uracil-DNA Glycosidase Human genes 0.000 description 2
- 108010072685 Uracil-DNA Glycosidase Proteins 0.000 description 2
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
- 208000000260 Warts Diseases 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 102000013165 exonuclease Human genes 0.000 description 2
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 230000000171 quenching effect Effects 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 201000010153 skin papilloma Diseases 0.000 description 2
- 238000002764 solid phase assay Methods 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- WGTODYJZXSJIAG-UHFFFAOYSA-N tetramethylrhodamine chloride Chemical compound [Cl-].C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C(O)=O WGTODYJZXSJIAG-UHFFFAOYSA-N 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 239000001226 triphosphate Substances 0.000 description 2
- 235000011178 triphosphate Nutrition 0.000 description 2
- 208000035657 Abasia Diseases 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- AHCYMLUZIRLXAA-SHYZEUOFSA-N Deoxyuridine 5'-triphosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 AHCYMLUZIRLXAA-SHYZEUOFSA-N 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108010010677 Phosphodiesterase I Proteins 0.000 description 1
- 108020004518 RNA Probes Proteins 0.000 description 1
- 239000003391 RNA probe Substances 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 101710172430 Uracil-DNA glycosylase inhibitor Proteins 0.000 description 1
- 238000002820 assay format Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000012864 cross contamination Methods 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 239000005549 deoxyribonucleoside Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000000295 emission spectrum Methods 0.000 description 1
- 238000000695 excitation spectrum Methods 0.000 description 1
- 108060003196 globin Proteins 0.000 description 1
- 102000018146 globin Human genes 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000007403 mPCR Methods 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- -1 nucleotide triphosphates Chemical class 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000011897 real-time detection Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000005382 thermal cycling Methods 0.000 description 1
- ANRHNWWPFJCPAZ-UHFFFAOYSA-M thionine Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 1
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- 239000010937 tungsten Substances 0.000 description 1
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
- 229940045145 uridine Drugs 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 229910052724 xenon Inorganic materials 0.000 description 1
- FHNFHKCVQCLJFQ-UHFFFAOYSA-N xenon atom Chemical compound [Xe] FHNFHKCVQCLJFQ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
- C12Q1/708—Specific hybridization probes for papilloma
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30494110P | 2010-02-16 | 2010-02-16 | |
| US61/304,941 | 2010-02-16 | ||
| CA2789456A CA2789456C (en) | 2010-02-16 | 2011-02-16 | Assay for detecting closely-related serotypes of human papillomavirus (hpv) |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2789456A Division CA2789456C (en) | 2010-02-16 | 2011-02-16 | Assay for detecting closely-related serotypes of human papillomavirus (hpv) |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2981303A1 CA2981303A1 (en) | 2011-08-25 |
| CA2981303C true CA2981303C (en) | 2020-06-30 |
Family
ID=44370063
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2981303A Active CA2981303C (en) | 2010-02-16 | 2011-02-16 | Assay for detecting closely-related serotypes of human papillomavirus (hpv) |
| CA2789456A Active CA2789456C (en) | 2010-02-16 | 2011-02-16 | Assay for detecting closely-related serotypes of human papillomavirus (hpv) |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2789456A Active CA2789456C (en) | 2010-02-16 | 2011-02-16 | Assay for detecting closely-related serotypes of human papillomavirus (hpv) |
Country Status (11)
| Country | Link |
|---|---|
| US (5) | US8658397B2 (enExample) |
| EP (1) | EP2536853B1 (enExample) |
| JP (1) | JP5965846B2 (enExample) |
| CN (1) | CN102822354B (enExample) |
| AU (1) | AU2011218215B2 (enExample) |
| CA (2) | CA2981303C (enExample) |
| ES (1) | ES2665465T3 (enExample) |
| MX (1) | MX340673B (enExample) |
| RU (1) | RU2558236C2 (enExample) |
| WO (1) | WO2011103159A2 (enExample) |
| ZA (1) | ZA201206530B (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2013205122B2 (en) | 2012-10-11 | 2016-11-10 | Gen-Probe Incorporated | Compositions and Methods for Detecting Human Papillomavirus Nucleic Acid |
| WO2020055834A2 (en) * | 2018-09-10 | 2020-03-19 | Memorial Sloan Kettering Cancer Center | Methods and compositions for detection of hpv dna and diagnosis and monitoring hpv-associated cancers |
| CN112961938B (zh) * | 2019-12-13 | 2022-06-07 | 浙江我武生物科技股份有限公司 | 检测人类乳头瘤病毒的方法和试剂盒 |
| RU2737619C1 (ru) * | 2019-12-27 | 2020-12-01 | Общество с ограниченной ответственностью "НекстБио" | Набор синтетических олигонуклеотидов для выявления ДНК вируса папилломы человека 52 типа высокого канцерогенного риска в слизистой оболочке цервикального канала |
| RU2722185C1 (ru) * | 2019-12-27 | 2020-05-28 | Общество с ограниченной ответственностью "НекстБио" | Набор синтетических олигонуклеотидов для выявления ДНК вируса папилломы человека 51 типа высокого канцерогенного риска в слизистой оболочке цервикального канала |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5447839A (en) | 1988-09-09 | 1995-09-05 | Hoffmann-La Roche Inc. | Detection of human papillomavirus by the polymerase chain reaction |
| CA2122203C (en) | 1993-05-11 | 2001-12-18 | Melinda S. Fraiser | Decontamination of nucleic acid amplification reactions |
| US5585477A (en) | 1993-07-13 | 1996-12-17 | Us Health | Poliovirus specific primers |
| US5538848A (en) | 1994-11-16 | 1996-07-23 | Applied Biosystems Division, Perkin-Elmer Corp. | Method for detecting nucleic acid amplification using self-quenching fluorescence probe |
| US5698394A (en) * | 1994-06-01 | 1997-12-16 | Board Of Regents Of The University Of Nebraska | Nucleotide sequences and methods for detection of Serpulina hyodysenteriae |
| US6511805B1 (en) | 1996-03-15 | 2003-01-28 | The Penn State Research Foundation | Methods for detecting papillomavirus DNA in blood plasma and serum |
| US6214555B1 (en) | 1996-05-01 | 2001-04-10 | Visible Genetics Inc. | Method compositions and kit for detection |
| CA2399364A1 (fr) * | 2000-02-08 | 2001-08-16 | Aventis Pharma S.A. | Procede de detection et de quantification d'adenovirus |
| PT1421200E (pt) * | 2001-08-23 | 2007-02-28 | Merck & Co Inc | Ensaios de pcr multiplex fluorescente para hpv usando múltiplos fluoróforos |
| SE0202897D0 (sv) * | 2002-10-01 | 2002-10-01 | Quantovir Ab | Method and kit for quantitative and qualitative determination of human papillomavirus |
| CN1720060B (zh) * | 2002-10-03 | 2011-12-14 | 惠氏控股公司 | 人乳头瘤病毒多肽和免疫原性组合物 |
| US20060257894A1 (en) | 2003-09-16 | 2006-11-16 | Michel Doumith | Molecular typing of listeria monocytogenes, hybridization supports and kits for said molecular typing |
| ATE474066T1 (de) * | 2005-11-15 | 2010-07-15 | Genoid Kft | Verfahren zum nachweis von pathogenen mittels molecular beacons |
| EP1997914A1 (en) * | 2007-06-01 | 2008-12-03 | Università Degli Studi Di Milano - Bicocca | Identification and quantification of oncogenic HPV nucleic acids by means of real-time PCR assays |
| EP2030924A1 (de) * | 2007-08-28 | 2009-03-04 | Müller Martini Holding AG | Einrichtung zum Verarbeiten von Druckprodukten |
| ES2584228T3 (es) | 2007-11-01 | 2016-09-26 | Self-Screen B.V. | Nuevo método de detección para los HPV cervicales |
-
2011
- 2011-02-16 ES ES11745156.7T patent/ES2665465T3/es active Active
- 2011-02-16 AU AU2011218215A patent/AU2011218215B2/en active Active
- 2011-02-16 RU RU2012139221/10A patent/RU2558236C2/ru active
- 2011-02-16 CN CN201180016387.4A patent/CN102822354B/zh active Active
- 2011-02-16 MX MX2012009406A patent/MX340673B/es active IP Right Grant
- 2011-02-16 US US13/028,589 patent/US8658397B2/en active Active
- 2011-02-16 WO PCT/US2011/025046 patent/WO2011103159A2/en not_active Ceased
- 2011-02-16 EP EP11745156.7A patent/EP2536853B1/en active Active
- 2011-02-16 JP JP2012553988A patent/JP5965846B2/ja active Active
- 2011-02-16 CA CA2981303A patent/CA2981303C/en active Active
- 2011-02-16 CA CA2789456A patent/CA2789456C/en active Active
-
2012
- 2012-08-30 ZA ZA2012/06530A patent/ZA201206530B/en unknown
-
2014
- 2014-02-12 US US14/179,113 patent/US9868997B2/en active Active
-
2017
- 2017-12-15 US US15/843,957 patent/US10865455B2/en active Active
-
2020
- 2020-11-11 US US17/094,908 patent/US11913083B2/en active Active
-
2024
- 2024-01-19 US US18/418,143 patent/US20240229169A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP2536853A2 (en) | 2012-12-26 |
| US20180127839A1 (en) | 2018-05-10 |
| BR112012020470A8 (pt) | 2022-05-10 |
| CA2981303A1 (en) | 2011-08-25 |
| CA2789456C (en) | 2017-11-21 |
| US20140256580A1 (en) | 2014-09-11 |
| CN102822354B (zh) | 2015-06-03 |
| US20210071272A1 (en) | 2021-03-11 |
| BR112012020470A2 (pt) | 2017-01-10 |
| US20240229169A1 (en) | 2024-07-11 |
| AU2011218215A1 (en) | 2012-09-13 |
| JP2013519395A (ja) | 2013-05-30 |
| US10865455B2 (en) | 2020-12-15 |
| CA2789456A1 (en) | 2011-08-25 |
| US8658397B2 (en) | 2014-02-25 |
| ES2665465T3 (es) | 2018-04-25 |
| MX2012009406A (es) | 2012-09-07 |
| RU2558236C2 (ru) | 2015-07-27 |
| WO2011103159A2 (en) | 2011-08-25 |
| MX340673B (es) | 2016-07-20 |
| RU2012139221A (ru) | 2014-03-27 |
| EP2536853B1 (en) | 2018-02-14 |
| US9868997B2 (en) | 2018-01-16 |
| ZA201206530B (en) | 2016-06-29 |
| US11913083B2 (en) | 2024-02-27 |
| JP5965846B2 (ja) | 2016-08-10 |
| US20110201516A1 (en) | 2011-08-18 |
| CN102822354A (zh) | 2012-12-12 |
| WO2011103159A3 (en) | 2012-01-12 |
| EP2536853A4 (en) | 2013-07-24 |
| AU2011218215B2 (en) | 2015-10-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240229169A1 (en) | Assay for detecting closely-related serotypes of human papillomavirus (hpv) | |
| US20050175987A1 (en) | Fluorescent multiplex hpv pcr assays using multiple fluorophores | |
| DK2425017T3 (en) | A method for typing of human papillomavirus HPV | |
| EP1806410A2 (en) | Fluorescent multiplex HPV PCR assays using multiple fluorophores | |
| US7993881B2 (en) | Method for detecting pathogens using molecular beacons | |
| US20100003665A1 (en) | Real-time HPV PCR Assays | |
| WO2017001544A1 (en) | Hpv detection method | |
| US20100203496A1 (en) | Fluorescent Multiplex HPV PCR Assays | |
| BR112012020470B1 (pt) | Ensaio multiplex, grupo de sonda e kit para detectar a presença ou ausência de múltiplos sorotipos de um organismo papilomavírus humano (hpv) em uma amostra biológica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20171003 |